TMEM9B

TMEM9B is a glycosylated single-span transmembrane protein that functions as an accessory β-subunit of the endosomal Cl⁻/H⁺ antiporters ClC-3, ClC-4, and ClC-5, directly binding these transporters to inhibit their activity, with PtdIns(3,5)P₂ stabilizing the interaction; cryo-EM structures show the related TMEM9 seals the cytosolic entrance to the Cl⁻ ion pathway, establishing a conserved mechanism of transport regulation (PMID:39202776, PMID:40670814, PMID:40437099). TMEM9B also operates in inflammatory signaling, acting downstream of RIP1 at the level of the TAK1 complex to activate NF-κB and MAPK pathways in response to TNF, IL-1β, and TLR ligands from its lysosomal/early endosomal localization (PMID:18541524). Additionally, TMEM9B is required downstream of the p53-p21 and p16-pRB tumor suppressor pathways for entry into cellular senescence (PMID:21740549).

1. 2008 High

   The first functional role for TMEM9B was established: it is a lysosomal/endosomal glycoprotein that activates NF-κB and MAPK inflammatory signaling by operating within the TAK1 complex downstream of RIP1, resolving TMEM9B's position in the innate immune signaling cascade.

   Evidence RNAi knockdown, cytokine assays, subcellular fractionation, and epistasis analysis across TNF, IL-1β, and TLR stimuli in mammalian cells

   PMID:18541524

   Open questions at the time

   • How TMEM9B, as a lysosomal membrane protein, physically engages the cytosolic TAK1 complex is undefined
   • Whether TMEM9B's signaling role depends on its later-identified ion transporter regulation is unknown
   • No structural information on TMEM9B's interaction with TAK1 complex components
2. 2011 Medium

   TMEM9B was positioned as an effector of tumor suppressor-driven senescence, showing that its loss bypasses senescence induced by both the p53-p21 and p16-pRB pathways, broadening its function beyond inflammation.

   Evidence Genome-wide RNAi screen for senescence bypass in conditionally immortalized human fibroblasts, validated by lentiviral shRNAmir silencing

   PMID:21740549

   Open questions at the time

   • Limited mechanistic follow-up: it is unknown whether TMEM9B promotes senescence via NF-κB/MAPK signaling, lysosomal function, or an independent mechanism
   • Single-lab finding without independent replication
   • No rescue experiment with re-expression of TMEM9B reported
3. 2024 High

   TMEM9B was identified as a direct binding partner and functional inhibitor of the endosomal ClC-3 and ClC-4 Cl⁻/H⁺ antiporters, establishing a previously unrecognized ion transport regulatory role separate from its signaling functions.

   Evidence Co-expression electrophysiology in Xenopus oocytes and HEK cells, FLIM-FRET for direct interaction, with specificity controls showing no binding to ClC-1 or ClC-7

   PMID:39202776

   Open questions at the time

   • Structural basis of how TMEM9B inhibits transporter currents was not yet resolved
   • Whether TMEM9B regulation occurs in native endosomal membranes was untested
   • Physiological consequence of TMEM9B-mediated ClC inhibition in vivo was unknown
4. 2025 High

   Cryo-EM structures and native endosomal crosslinking mass spectrometry independently confirmed TMEM9B as a bona fide β-subunit of ClC-3/4/5 in their physiological membrane context, with atomic-resolution detail showing that PtdIns(3,5)P₂ stabilizes the interaction and the related TMEM9 inhibits by occluding the Cl⁻ pathway.

   Evidence Cryo-EM structure determination with lipid binding assays and electrophysiology (Nat. Struct. Mol. Biol.); crosslinking MS of purified early endosomes with AlphaFold modeling and validation in induced neurons (Nature)

   PMID:40437099 PMID:40670814

   Open questions at the time

   • Whether TMEM9B occludes the Cl⁻ pathway identically to TMEM9 or uses a distinct inhibitory mechanism is not fully resolved
   • Physiological consequences of disrupting the TMEM9B–ClC interaction in animal models are unexplored
   • Relationship between TMEM9B's ion channel regulatory role and its NF-κB/senescence functions remains unconnected

• A central unresolved question is whether TMEM9B's two established roles — endosomal Cl⁻/H⁺ antiporter regulation and inflammatory/senescence signaling — are mechanistically linked, for instance through lysosomal pH or endosomal acidification, or represent independent functions.
• No study has tested whether TMEM9B's modulation of ClC transporter activity alters endosomal pH sufficiently to affect NF-κB/MAPK signaling
• In vivo loss-of-function models (knockout mice) have not been reported
• Disease associations from direct genetic evidence are absent